Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
23,597,628
-
Total 13F shares
-
4,894,669
-
Share change
-
+3,206,219
-
Total reported value
-
$13,494,162
-
Price per share
-
$2.77
-
Number of holders
-
27
-
Value change
-
+$5,623,419
-
Number of buys
-
18
-
Number of sells
-
7
Institutional Holders of Rein Therapeutics, Inc. - Common Stock, $0.001 par value (RNTX) as of Q2 2024
As of 30 Jun 2024,
Rein Therapeutics, Inc. - Common Stock, $0.001 par value (RNTX) was held by
27 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,894,669 shares.
The largest 10 holders included
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO, Alyeska Investment Group, L.P., VANGUARD GROUP INC, Nantahala Capital Management, LLC, Cable Car Capital LLC, Prosight Management, LP, Senvest Management, LLC, GEODE CAPITAL MANAGEMENT, LLC, Sigma Planning Corp, and Kepos Capital LP.
This page lists
27
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.